ANZCHOG Children’s Cancer Clinical Trials Repository

Study Title
ONC201-108: ONC201 for the Treatment of Newly Diagnosed H3 K27M-mutant Diffuse Glioma Following Completion of Radiotherapy: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study
Protocol ID
ONC201-108
Condition/s
H3 K27M-mutant diffuse glioma
Diagnosis Stage
Newly diagnosed
Location
NSW, WA, TAS
Sponsor
Chimerix
Links
External Registry ≫
Trial Status
Open
Sites
Sydney Children's Hospital
Perth Children's Hospital
Royal Hobart Hospital
Study Type
Treatment
Phase
Phase 3
Age Eligibility
Child, Adult, Older Adult
International registry ID's
NCT05580562
Back to Registry
Study Title ONC201-108: ONC201 for the Treatment of Newly Diagnosed H3 K27M-mutant Diffuse Glioma Following Completion of Radiotherapy: A Randomized Double-Blind Placebo-Controlled Multicenter Study
Protocol ID ONC201-108
Disease (Sub Disease) H3 K27M-mutant diffuse glioma
Diagnosis Stage Newly diagnosed
Location NSW / WA / TAS
Sponsor Chimerix
Links https://clinicaltrials.gov/study/NCT05580562
Trial Status Open
Sites Sydney Children's Hospital / Perth Children's Hospital/ Royal Hobart Hospital
Study Type Treatment
Phase Phase 3
Age Eligibility Child, Adult, Older Adult
International registry ID's NCT05580562

Join our newsletter

"*" indicates required fields

This field is for validation purposes and should be left unchanged.

Email info@anzchog.org   |  

Level 6, TRF Building, Hudson Institute, 27-31 Wright St, Clayton VIC 3168

ANZCHOG acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait Islander cultures, and to Elders both past and present. We acknowledge Māori as tangata whenua of Aotearoa New Zealand and as Treaty partners with the Crown as agreed in Te Tiriti o Waitangi. 

We are committed to creating a safe and welcoming environment that embraces all backgrounds, cultures, sexualities, genders and abilities.